Sclerostin, an inhibitor of the Wnt signaling pathway, inhibits bone formation. In a study of
vascular biopsies of patients undergoing kidney transplantation, Qureshi et al. demonstrate …

Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone
formation by suppressing osteocytes differentiation and function. Patients with chronic …

Context: Sclerostin, a Wnt antagonist produced by osteocytes, regulates osteoblast activity
and is a well-established key player in bone turnover. Recent data indicate that the Wnt …

Background Sclerostin is an osteocyte-derived inhibitor of the Wnt pathway and has been
shown to play a key role in chronic kidney disease-mineral and bone disorder (CKD-MBD) …

Abstract Background Sclerostin is a Wnt pathway antagonist regulating osteoblast activity
and bone turnover, and it plays a role in cardiovascular calcification processes. Previous …

The causes of the increased cardiovascular risk associated with kidney diseases partly
reside in the chronic kidney disease–mineral bone disorder (CKD–MBD) syndrome. Three …

Background The process of vascular calcification has been associated with the canonical
Wnt/β-catenin signalling pathway in cell cultures and animal studies. The relationship …

Abstract Background Sclerostin is a Wnt pathway antagonist regulating osteoblast activity
and bone turnover. Here, we assessed the potential association of sclerostin with the …

Context: Vascular calcification (VC) is prevalent and progressive in renal transplant
recipients (RTRs). Recent cross-sectional data suggest that activated Wnt signaling …

Background Derangements in bone metabolism and vascular calcification (VC) substantially
contribute to the accelerated cardiovascular morbidity and mortality in chronic kidney …